Subramanian Nithya, Kanwar Jagat R, Kanwar Rupinder K, Krishnakumar Subramanian
1 Department of Nanobiotechnology, Vision Research Foundation, Kamalnayan Bajaj Institute for Research in Vision and Ophthalmology , Chennai, India .
Nucleic Acid Ther. 2015 Feb;25(1):47-52. doi: 10.1089/nat.2014.0507. Epub 2014 Dec 16.
The miR-17∼92. or oncomiR-1, cluster encodes oncogenic microRNAs (miRNAs), and it also promotes retinoblastoma (RB) tumor formation. Antagomir and miRNA mimics based approaches are widely tried against oncogenic and tumor suppressive miRNAs. Other methods for targeting cancer related miRNAs are still under development. In the current study, we focused on the pri-miRNA-17∼92 aptamer (pri-apt), which can potentially replace the mix of five antagomirs by one aptamer that function to abrogate the maturation of miR-17, miR-18a, and miR-19b (P<0.05) for targeting RB. We used RB cell lines WERI-Rb1 and Y79 as an in vitro model. Cellular changes upon transfecting the pri-apt led to S-phase arrest in WERI-Rb1 cells and onset of apoptosis in both Y79 and WERI-Rb1 cell lines. There was increased cytotoxicity as measured by lactate dehydrogenase activity in pri-apt treated Y79 cells (P<0.05), and significant inhibition of cell proliferation was observed in both of the cell lines. Thus we showed the antiproliferative property of pri-apt in RB cell lines, which can be readily modified by developing appropriate vectors for the delivery of the aptamer specifically to cancer cells.
miR-17∼92(又称致癌miR-1)簇编码致癌性微小RNA(miRNA),它还能促进视网膜母细胞瘤(RB)的肿瘤形成。基于抗miR和miRNA模拟物的方法被广泛用于对抗致癌性和肿瘤抑制性miRNA。其他靶向癌症相关miRNA的方法仍在研发中。在本研究中,我们聚焦于初级miRNA-17∼92适配体(pri-apt),它有可能用一种适配体替代五种抗miR的混合物,该适配体的作用是消除miR-17、miR-18a和miR-19b的成熟(P<0.05)以靶向RB。我们使用RB细胞系WERI-Rb1和Y79作为体外模型。转染pri-apt后细胞发生的变化导致WERI-Rb1细胞停滞于S期,Y79和WERI-Rb1细胞系均出现凋亡。pri-apt处理的Y79细胞中,通过乳酸脱氢酶活性测定的细胞毒性增加(P<0.05),并且在这两种细胞系中均观察到细胞增殖受到显著抑制。因此,我们展示了pri-apt在RB细胞系中的抗增殖特性,通过开发合适的载体将适配体特异性递送至癌细胞,该特性可以很容易地被修饰。